Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Andrea Aiello; Anna D'Ausilio; Roberta Lo Muto; Francesca Randon; Luca Laurenti

doi:10.1080/20016689.2017.1393308

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Andrea Aiello^*
, Anna D'Ausilio
, Roberta Lo Muto
, Francesca Randon
, Luca Laurenti

^*Autore corrispondente per questo lavoro

Creativ–Ceutical
Janssen-Cilag SpA

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

Lingua originale	Inglese
pagine (da-a)	N/A-N/A
Rivista	Journal of Market Access and Health Policy
Volume	5
Numero di pubblicazione	5
DOI	https://doi.org/10.1080/20016689.2017.1393308
Stato di pubblicazione	Pubblicato - 2017

All Science Journal Classification (ASJC) codes

Politiche della Salute
Informatica della Salute

Keywords

Italy
Waldenström Macroglobulinemia
cost-effectiveness analysis
ibrutinib

Accesso al documento

10.1080/20016689.2017.1393308

Altri file e collegamenti

Cita questo

@article{2baa781b47054d7d8086490fce6a305c,

title = "Cost-effectiveness analysis of ibrutinib in patients with Waldenstr{\"o}m macroglobulinemia in Italy",

abstract = "Ibrutinib has recently been approved in Europe for Waldenstr{\"o}m Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).",

keywords = "Italy, Waldenstr{\"o}m Macroglobulinemia, cost-effectiveness analysis, ibrutinib, Italy, Waldenstr{\"o}m Macroglobulinemia, cost-effectiveness analysis, ibrutinib",

author = "Andrea Aiello and Anna D'Ausilio and \{Lo Muto\}, Roberta and Francesca Randon and Luca Laurenti",

year = "2017",

doi = "10.1080/20016689.2017.1393308",

language = "English",

volume = "5",

pages = "N/A--N/A",

journal = "Journal of Market Access and Health Policy",

issn = "2001-6689",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

AU - Aiello, Andrea

AU - D'Ausilio, Anna

AU - Lo Muto, Roberta

AU - Randon, Francesca

AU - Laurenti, Luca

PY - 2017

Y1 - 2017

N2 - Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

AB - Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

KW - Italy

KW - Waldenström Macroglobulinemia

KW - cost-effectiveness analysis

KW - ibrutinib

KW - Italy

KW - Waldenström Macroglobulinemia

KW - cost-effectiveness analysis

KW - ibrutinib

UR - https://publicatt.unicatt.it/handle/10807/135397

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85068828942&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068828942&origin=inward

U2 - 10.1080/20016689.2017.1393308

DO - 10.1080/20016689.2017.1393308

M3 - Article

SN - 2001-6689

VL - 5

SP - N/A-N/A

JO - Journal of Market Access and Health Policy

JF - Journal of Market Access and Health Policy

IS - 5

ER -

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo